🇺🇸 FDA
Patent

US 6890917

Geldanamycin derivative and method of treating cancer using same

expired A61PA61P35/00A61P43/00

Quick answer

US patent 6890917 (Geldanamycin derivative and method of treating cancer using same) held by The United States of America, as represented by the Department of Health and Human Services expires Mon May 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue May 10 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61P, A61P35/00, A61P43/00